Whalen Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Whalen Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.75M	Buy	11,049 +9,460	+595%	+$1.28M	0.79%	36
2026 Q1	$203K	Buy	+1,589	New	+$198K	0.11%	173
2025 Q1	–	Sell	-2,346	Closed	-$211K	–	180
2024 Q4	$211K	Buy	2,346 +61	+3%	+$5.91K	0.15%	135
2024 Q3	$226K	Sell	2,285 -18,778	-89%	-$1.84M	0.16%	105
2024 Q2	$1.95M	Buy	21,063 +5,336	+34%	+$478K	1.55%	17
2024 Q1	$1.49M	Buy	15,727 +1,854	+13%	+$172K	1.11%	16
2023 Q4	$1.24M	Buy	+13,873	New	+$1.03M	1.12%	13

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Whalen Wealth Management's XBI Position: Q2 2026 in Review

Whalen Wealth Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 595% in Q2 2026, buying an estimated $1.28M and bringing the position to 11,049 shares worth $1.75M. The position accounts for 0.79% of the portfolio, ranked #36.

Whalen Wealth Management first reported a position in XBI in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.95M in Q2 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Whalen Wealth Management held 11,049 shares of State Street SPDR S&P Biotech ETF worth $1.75M as of Q2 2026.
Whalen Wealth Management bought 9,460 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.28M.
State Street SPDR S&P Biotech ETF made up 0.79% of Whalen Wealth Management's portfolio in Q2 2026, its #36 holding.
Whalen Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 7 quarters since.
Whalen Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $1.95M in Q2 2024.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Whalen Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.